TELAHIGH SIGNALFINANCIAL10-K

TELA experienced a severe 78% collapse in stockholders' equity to just $6.3M despite revenue growth, indicating potential dilution, losses, or balance sheet restructuring that dramatically weakened the company's financial position.

The massive equity decline combined with 29% increase in total liabilities suggests TELA is burning through capital faster than it can generate value, despite improved operating performance. The addition of Nasdaq delisting risk language indicates the company may be struggling with stock price compliance, creating potential liquidity and financing challenges.

Comparing 2026-03-25 vs 2025-03-21View on EDGAR →
FINANCIAL ANALYSIS

TELA presents a mixed but concerning financial picture with revenue growing 16% to $80.3M and operating cash flow losses improving 32% to -$28.2M, demonstrating operational progress. However, the company's financial foundation deteriorated severely with stockholders' equity plummeting 78% to only $6.3M while total liabilities surged 29% to $75.1M, and interest expense increased 29% to $5.2M. This dramatic weakening of the balance sheet despite operational improvements suggests significant equity dilution, accumulated losses, or debt restructuring that poses substantial risk to shareholders.

FINANCIAL STATEMENT CHANGES
Stockholders Equity
Balance Sheet
-77.8%
$28.5M$6.3M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Capital Expenditure
Cash Flow
-54.7%
$989K$448K

Capex reduced 54.7% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Operating Cash Flow
Cash Flow
+32.2%
-$41.6M-$28.2M

Operating cash flow surged 32.2% — exceptional cash generation, highest quality earnings signal.

Total Liabilities
Balance Sheet
+29.2%
$58.1M$75.1M

Liabilities increased 29.2% — monitor debt-to-equity ratio and interest coverage.

Interest Expense
P&L
+28.9%
$4.1M$5.2M

Interest costs rose 28.9% — monitor debt levels and coverage ratio in rising rate environment.

Gross Profit
P&L
+16.9%
$46.5M$54.3M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Revenue
P&L
+15.8%
$69.3M$80.3M

Revenue growing 15.8% — solid top-line momentum, watch margins for quality of growth.

Current Liabilities
Balance Sheet
+15.2%
$15.6M$18.0M

Current liabilities rose 15.2% — increased short-term obligations, watch current ratio.

Inventory
Balance Sheet
-13.8%
$12.8M$11.0M

Inventory reduced 13.8% — lean inventory management or demand outpacing supply.

LANGUAGE CHANGES
NEW — 2026-03-25
PRIOR — 2025-03-21
ADDED
As of March 16, 2026, the registrant had 44,740,371 shares of Common Stock, $0.001 par value per share, outstanding.
If competitors enter into supply contracts with our customers that disfavor our products or discourage their use, our commercial success could be adversely affected.
Risks Related to Intellectual Property Matters We may need to license intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.
If we fail to comply or regain compliance with the continued listing standards of Nasdaq, we may be delisted and the price of our common stock, or ability to access the capital markets and our financial condition could be negatively impacted.
In April 2024, we launched OviTex IHR Reinforced Tissue Matrix, a new OviTex configuration specifically designed to address inguinal hernia procedures performed robotically and laparoscopically in the U.S., followed by a launch in the European markets in June 2025.
+7 more — sign up free →
REMOVED
As of March 14, 2025, the registrant had 39,551,098 shares of Common Stock, $0.001 par value per share, outstanding.
, including regulatory developments due to changes in the U.S.
To successfully market and sell our products in markets outside of the U.S., we must address many international business risks with which we have limited experience.
In April 2024, we launched OviTex IHR Reinforced Tissue Matrix, a new OviTex configuration specifically designed to address inguinal hernia procedures performed robotically and laparoscopically.
We also continue to enroll patients in our OPERA study, a retrospective-prospective trial evaluating the safety profile of OviTex PRS in previous pre-pectoral and sub-pectoral implant-based breast reconstructions.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →